- Imatinib Plasma Monitoring-Guided Dose Modification for Managing Imatinib-Related Toxicities in Gastrointestinal Stromal Tumor Patients
-
Yoon S, Ryu MH, Yoo C, Beck MY, Ryoo BY, Kang YK
- KMID: 1793034
- J Korean Med Sci.
- 2013 Aug;28(8):1248-1252.
- doi: 10.3346/jkms.2013.28.8.1248
Imatinib, the first-line treatment in patients with advanced gastrointestinal stromal tumors (GIST), is generally well tolerated, although some patients have difficulty tolerating the standard dose of 400 mg/day. Adjusting imatinib... -
- CITED
-
- Close
- SHARE
-
- Close
- Severe Imatinib-Associated Skin Rash in Gastrointestinal Stromal Tumor Patients: Management and Clinical Implications
-
Park SR, Ryu MH, Ryoo BY, Beck MY, Lee IS, Choi MJ, Lee MW, Kang YK
- KMID: 2152272
- Cancer Res Treat.
- 2016 Jan;48(1):162-170.
- doi: 10.4143/crt.2015.017
PURPOSE: This study evaluated the incidence of imatinib-associated skin rash, the interventional outcomes of severe rash, and impact of severe rash on the outcomes of imatinib treatment in gastrointestinal stromal... -
- CITED
-
- Close
- SHARE
-
- Close
